Medigene AG (MDGEF)
- Previous Close
2.2965 - Open
2.4300 - Bid --
- Ask --
- Day's Range
2.2965 - 2.2965 - 52 Week Range
1.5000 - 2.8400 - Volume
500 - Avg. Volume
57 - Market Cap (intraday)
56.408M - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.
www.medigene.comRecent News: MDGEF
Performance Overview: MDGEF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDGEF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDGEF
Valuation Measures
Market Cap
44.02M
Enterprise Value
29.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.73
Price/Book (mrq)
2.79
Enterprise Value/Revenue
4.86
Enterprise Value/EBITDA
-2.01
Financial Highlights
Profitability and Income Statement
Profit Margin
-268.10%
Return on Assets (ttm)
-24.21%
Return on Equity (ttm)
-55.69%
Revenue (ttm)
6.03M
Net Income Avi to Common (ttm)
-16.18M
Diluted EPS (ttm)
-0.6700
Balance Sheet and Cash Flow
Total Cash (mrq)
16.67M
Total Debt/Equity (mrq)
14.00%
Levered Free Cash Flow (ttm)
-6.93M
Research Analysis: MDGEF
Company Insights: MDGEF
MDGEF does not have Company Insights